24 documents found, page 1 of 3
Bdnf-NRF2 crosstalk in depression disorder
Santos, Marlene; Caldevilla, Renato; Morais, Stephanie; Carvalho, Serafim; Medeiros, Rui; Barroso, Maria FátimaThe World Health Organization estimates that major depressive disorder (MDD) affects over 264 million individuals globally, posing a significant public health challenge. Treatment-resistant depression (TRD) represents a severe form of MDD with poor treatment outcomes. Genetic variations are known to impact MDD treatment responses, yet genome-wide association studies have struggled to identify consistent marker ...
ABCB1 C1236T, G2677TA and C3435T genetic polymorphisms and antidepressant respo...
Santos, Marlene; Lima, Luís; Carvalho, Serafim; Brandão, Andreia; Barroso, Fátima; Cruz, Agostinho; Medeiros, RuiP-glycoprotein (P-GP) is a transporter molecule expressed on the apical surface of capillary endothelial cells of the Blood–Brain Barrier (BBB), whose activity heavily influences drug distribution, including antidepressants. This transporter is encoded by ABCB1 gene, and genetic variations within ABCB1 gene have been proposed to affect drug efflux and have been previously associated with depression. In this con...
The impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and...
Santos, Marlene; Lima, Luis; Carvalho, Serafim; Mota-Pereira, Jorge; Pimentel, Paulo; Maia, Dulce; Correia, Diana; Barroso, M. Fátima; Gomes, SofiaThis study aimed to investigate the influence of genetic variants in neuroplasticity-related genes on antidepressant treatment phenotypes. The BDNF-TrkB signaling pathway, as well as the downstream kinases Akt and ERK and the mTOR pathway, have been implicated in depression and neuroplasticity. However, clinicians still struggle with the unpredictability of antidepressant responses in depressed patients. We gen...
Design of an electrochemical genosensor for the BDNF gene polymorphism sequence...
Caldevilla, Renato; Morais, Stephanie; Carvalho, Serafim; Medeiros, Rui; Delerue-Matos, Cristina; Cruz, Agostinho; Santos, Marlene; Barroso, M. FátimaThe BDNF gene is associated with high degrees of variability in antidepressant treatments. The Val66Met polymorphism is widely known as a source of this variability, warranting growing interest in genotyping patients that undergo antidepressant treatment to better suit their needs. This paper reports on an electrochemical genosensing platform, based on gold electrodes, capable of detecting this polymorphism, th...
Comorbilidade de perturbação de personalidade Borderline e síndroma do cólon ir...
Martins, Cátia Priscila; Caetano, Filipa; Almeida, Hugo; Carvalho, SerafimIntrodução: O síndroma do cólon irritável (SCI) é uma perturbação gastrointestinal funcional comum nos países ocidentais, cuja sintomatologia inclui distensão e/ou dor abdominal e alterações do trânsito intestinal, como diarreia e/ou obstipação (critérios de Roma IV). A Perturbação de Personalidade Borderline (PPB) é pautada por instabilidade interpessoal e desregulação afetiva e comportamental. As queixas somá...
Propriedades Psicométricas da Escala de Cuidado do Questionário de Experiências...
Carvalho, Serafim; Pinto-Gouveia, José; Pimentel, Paulo; Castilho, Paula; Maia, Dulce; Pereira, Jorge MotaCertain experiences in childhood, as neglect, antipathy or child abuse and adversity in general are predictors of illness in adulthood. Existing interviews for evaluation of experiences are too long making them useful only on small samples. Childhood experiences investigation through a self-answering questionnaire enables to carry out a research on larger samples. In this paper, we present the Scale of Care (SC...
IL6-174G > C genetic polymorphism influences antidepressant treatment outcome
Carvalho, Serafim; Santos, Marlene; Lima, Luís; Mota-Pereira, Jorge; Pimentel, Paulo; Maia, Dulce; Correia, Diana; Gomes, Sofia; Cruz, AgostinhoMajor depressive disorder is a condition associated with dysregulated cytokine levels; among these, IL6. Furthermore, genetic variations within cytokine genes have been proposed to predict antidepressant treatment outcome. This study aims to evaluate the role of IL6-174G > C and IL6R D358A A > C functional poly-morphisms in antidepressant treatment phenotypes, specifically remission, relapse, and treatment resi...
The role of IL18-607C > A and IL18-137G > C promoter polymorphisms in antidepre...
Santos, Marlene; Carvalho, Serafim; Lima, Luís; Mota-Pereira, Jorge; Pimentel, Paulo; Maia, Dulce; Correia, Diana; Gomes, Sofia; Cruz, AgostinhoRecent studies suggest that immune activation and cytokines, such as IL-18, are involved in depression. IL-18 is expressed in brain and is increased in patients with moderate to severe depression. In this study we aim to evaluate the role of IL18-607C > A and IL18-137G > C promoter polymorphisms in antidepressant treatment phenotypes, specifically relapse and treatment resistant depression (TRD). We genotyped t...
Role of pharmacogenomics in predicting antidepressant response and individualiz...
Santos, Marlene; Carvalho, Serafim; Lima, Luís; Mota-Pereira, Jorge; Pimentel, Paulo; Maia, Dulce; Correia, Diana; Gomes, Sofia; Cruz, AgostinhoMajor Depressive Disorder (MDD) is a highly prevalent chronic psychiatric condition with significant morbidity. Despite several antidepressants drugs (AD) available, a wide fraction of patients fail to respond, present relapse or display treatment resistant depression (TRD). Pharmacogenomics could help identify patients at risk of relapse or TRD and possibly have a direct impact on personalizing therapy. Additi...
FAS -670A>G genetic polymorphism Is associated with treatment resistant depression
Santos, Marlene; Carvalho, Serafim; Lima, Luís; Mota-Pereira, Jorge; Pimentel, Paulo; Maia, Dulce; Correia, Diana; Gomes, Sofia; Cruz, AgostinhoHippocampal neurogenesis has been suggested as a downstream event of antidepressants (AD) mechanism of action and might explain the lag time between AD administration and the therapeutic effect. Despite the widespread use of AD in the context of Major Depressive Disorder (MDD) there are no reliable biomarkers of treatment response phenotypes, and a significant proportion of patients display Treatment Resistant ...